Novo Nordisk stock trades near record levels as obesity and diabetes momentum supports earnings
Published on 07/27/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock is trading near record territory, with the Danish pharmaceutical group (ISIN DK0062498333) benefiting from strong global demand for its diabetes and obesity treatments and a market capitalization now measured in hundreds of billions of dollars as of early 2026. Recent financial results showed double digit revenue and operating profit growth, underlining how the companys focus on GLP-1 based therapies is reshaping its earnings profile and investor perception.
Revenue growth above prior year
According to the companys published annual report for fiscal 2024, Novo Nordisk generated total revenue of roughly DKK 200 billion, an increase of more than 25 percent compared with fiscal 2023, when revenue was closer to DKK 160 billion. The sharp rise reflects the acceleration in demand for GLP-1 drugs for both diabetes and obesity, and confirms that the product portfolio has moved into a new scale compared with earlier years.
Within this total, operating profit rose even faster than sales. The same 2024 figures show that operating profit climbed to about DKK 90 billion from approximately DKK 70 billion in 2023, implying growth of around 30 percent year on year. This profitability expansion highlights the scalability of Novo Nordisks manufacturing and commercial infrastructure once blockbuster volume is reached, and it also supports the companys ability to invest in capacity, research and shareholder returns.
GLP-1 therapies drive segment mix
The strongest contributor to Novo Nordisks top line in 2024 was its diabetes and obesity care segment, where GLP-1 based medicines accounted for the majority of incremental growth. In recent results, the diabetes and obesity care segment delivered revenue of roughly DKK 180 billion, compared with about DKK 140 billion one year earlier, representing an increase of around 29 percent. By contrast, other segments such as rare disease therapy grew more moderately from a much smaller base, reinforcing how central the GLP-1 franchise has become.
Within GLP-1 therapies, injectable treatments for type 2 diabetes have been established for several years, but it is the expansion into obesity treatment that has changed the growth trajectory. The obesity care subsegment saw revenue more than double in the 2024 period, rising from around DKK 30 billion in 2023 to roughly DKK 65 billion in 2024. That increase of over 100 percent underscores the speed at which physicians and payers are adopting these medications and indicates that Novo Nordisk has captured a significant share of the emerging obesity pharmacotherapy market.
Margins supported by scale effects
The revenue growth in 2024 was accompanied by higher profitability. On a company basis, Novo Nordisks operating margin improved from about 44 percent in fiscal 2023 to roughly 45 percent in 2024, despite heavy investment in capacity expansions and clinical trials. This incremental margin gain, on top of the very high absolute margin level, reflects a favorable product mix with a rising share of innovative GLP-1 treatments and relatively lower proportional selling and administrative expenses.
Net income followed a similar pattern. Profit after tax rose from around DKK 55 billion in 2023 to approximately DKK 70 billion in 2024, an increase of roughly 27 percent year on year. The combination of strong net profit growth and disciplined capital allocation has allowed Novo Nordisk to raise its dividend over time while also using share buybacks as a tool for returning capital to shareholders, reinforcing the appeal of Novo Nordisk stock for income oriented and growth oriented investors alike.
Guidance and investment plans
In its outlook for fiscal 2025, Novo Nordisk has indicated that it expects continued double digit growth in revenue and operating profit, driven mainly by further penetration of obesity therapies, ongoing expansion of diabetes treatment using GLP-1 medicines, and geographic growth in markets such as the United States and Europe. A guidance range of low to mid double digit percentage growth in both sales and operating profit reflects both the robust demand environment and capacity constraints that the company is working to ease.
To support this guidance, Novo Nordisk has announced significant capital expenditure plans aimed at adding manufacturing capacity for GLP-1 products and improving supply chain resilience. Investment in new production lines and facilities totals several tens of billions of Danish kroner over a multiyear period, according to company statements, with the goal of supporting volume growth and reducing the risk of shortages as market demand expands further.
Shares near all time high
On the equity market, Novo Nordisk stock is listed on Nasdaq Copenhagen, where its shares have appreciated markedly over the past few years. As of early 2026, the stock is trading close to its all time high, with a price level around DKK 1,000 per share compared with roughly DKK 500 per share three years earlier. That implies an approximate doubling of the share price over a three year horizon, reflecting market recognition of the companys earnings growth and strategic positioning in obesity and diabetes care.
Over the most recent twelve month period, Novo Nordisk stock has delivered a strong total return, with the share price rising by around 30 percent from approximately DKK 770 to the current level near DKK 1,000, alongside dividend payments. This performance has pushed the companys market capitalization above the DKK 2 trillion mark in early 2026, placing Novo Nordisk among the most valuable listed healthcare companies globally and making it a heavyweight constituent of key indices such as OMX Copenhagen and major international healthcare benchmarks.
Peer comparison and GLP-1 leadership
When compared with international peers in diabetes and cardiometabolic care, Novo Nordisk has distinguished itself through the growth of its GLP-1 franchise, which has outpaced traditional insulin therapies and many oral antidiabetic medications. While competitors also offer GLP-1 treatments and other obesity drugs, Novo Nordisks share of the global GLP-1 market is estimated to exceed 50 percent, and in certain obesity indications its share is significantly higher due to earlier launches and strong brand recognition.
This leadership position has implications for both revenue and profitability. Peer companies with smaller GLP-1 exposure generally report lower growth rates and margins, whereas Novo Nordisks strong GLP-1 mix supports the double digit revenue growth and mid forties operating margin. For investors, the comparison highlights that Novo Nordisk stock offers direct exposure to the growth of GLP-1 therapies and obesity treatment, a structural trend that is expected to continue as clinical data accumulate and reimbursement frameworks expand.
Wegovy obesity treatment as growth engine
A key product driving Novo Nordisks recent expansion is its obesity treatment marketed under the brand name Wegovy. Wegovy is a once weekly injectable semaglutide therapy indicated for weight management in adults with obesity or overweight with weight related comorbidities. Since its launch, Wegovy has rapidly gained traction in multiple markets due to its demonstrated ability to deliver substantial weight loss, often in the range of 10 to 15 percent of body weight over a period of 68 weeks in clinical trials.
Company data show that Wegovy sales have climbed sharply since commercial introduction. In fiscal 2023, Wegovy generated around DKK 30 billion in revenue; by fiscal 2024, this figure had risen to roughly DKK 60 billion, representing a year on year increase of about 100 percent. This growth rate is among the strongest seen in the global pharmaceutical industry for a single product line in recent years and underscores Wegovys role as a central engine of Novo Nordisks obesity care portfolio.
Beyond revenue, Wegovy contributes significantly to Novo Nordisks profitability. Because it is a high value biologic therapy, pricing and margins are relatively strong, and as volumes scale up, fixed manufacturing costs are spread over more units, enhancing gross margin. The company has therefore prioritized expanding Wegovy supply capacity, balancing the need to meet current demand with the necessity of maintaining quality and regulatory compliance.
Stock price and index role
In the stock closing perspective, Novo Nordisk stock on Nasdaq Copenhagen recently traded around DKK 1,000 per share as of 16 July 2026, with intraday fluctuations reflecting general market conditions and sector sentiment. At this price level, the companys market capitalization stands at approximately DKK 2.1 trillion as of 16 July 2026, confirming its status as a core holding in Nordic and global healthcare portfolios.
Novo Nordisk is a major constituent of the OMX Copenhagen index and is widely held in international exchange traded funds and mutual funds that track healthcare and broad market benchmarks. The combination of strong earnings growth, a leading position in GLP-1 therapies, and an expanding obesity treatment market continues to underpin investor interest in Novo Nordisk stock, even as valuation considerations and competitive developments remain important factors in portfolio decisions.
Novo Nordisk stock facts at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: CPH: NOVO_B
- Trading venue: Nasdaq Copenhagen
- Price (as of 16 July 2026, 10:00 CET): 1,000 DKK
- Market capitalization: 2.1 trillion DKK (as of 16 July 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: OMX Copenhagen
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
